New Drugs: Pirfenidone a new hope in diabetic kidney disease.
By admin
Published: August 19, 2009
Diabetic nephropathy may be slowed by several means, the standard of care is blood pressure control, prescription of drugs which reduce protein in the urine and dietary changes. However the condition is almost always progressive despite these interventions.
Pirfenidone is not a particularly new drug, it has been known as an antifibrotic agent in that it reduces the formation of the primary constituent of scar tissue. Scar tissue referred to as fibrosis at the microscopic level forms as a consequence of inflammation during the process of healing.
Diabetic kidney disease has been associated with a unique type of scarring which occurs in the portion of the kidney responsible for filtering the blood. Over time this delicate filter is destroyed by fibrosis.
http://www.chemblink.com/products/53179-13-8.htm
The current study found that pirfenidone when given to laboratory mice reduced the damage to their kidneys by reducing the precursors of inflammation that lead to scarring. This is exciting news as pirfenidone directly targets a pathway that was previously not directly influenced by current therapy. This would therefore be a valuable adjunctive medication to be used alongside established treatment should the drug live up to its promise.
|
About Roger: Dr. Roger Smith is a nephrologist currently employed to the government of Jamaica. He is the Nephrologist in charge of Spanish Town Dialysis Unit. His interests are lupus nephritis and other glomerulopathies. He was previously a lecturer in Nephrology at the University of the West Indies in the Department of Internal Medicine and Coordinator of the Urogenital Module before moving into private and government practice. |
Tagged with: Treatment
